Peroxisome proliferator-activated receptors (PPARS): Novel therapeutic targets in renal disease [3] (multiple letters)

Kidney International

Volumn 61, Issue 1, 2002, Pages 354-355

  Broeders, Nilufer ^a   Abramowicz, Daniel ^a   Guan, Youfei ^a   Breyer, Matthew D ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CIPROFIBRATE; CREATININE; CYCLOOXYGENASE 2; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROSTAGLANDIN;

CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOXICITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; RHABDOMYOLYSIS; VASODILATATION;

EID: 0036147451     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00129.x     Document Type: Letter

References (4)

1. Y.F. Guan M.D. Breyer Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease Kidney Int 60 2001 14 30
2. N. Broeders C. Knoop M. Antoine Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15 2000 1993 1999
3. S. Westphal J. Dierkes C. Luley Effects of fenofibrate and gemfibrozil on plasma homocysteine Lancet 358 2001 39 40
4. B. Staels W. Koenig A. Habib Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators Nature 393 1998 790 793 10.1038/31701